PCOS has a new name, and the reason is metabolic

On 12 May 2026 a multistep global consensus process concluded that polycystic ovary syndrome would be renamed polyendocrine metabolic ovarian syndrome, shortened to PMOS. The process was led by Professor Helena Teede with the Androgen Excess and PCOS Society and the patient organisation Verity, and 56 patient and professional organisations signed up to it, the Endocrine Society among them.

The condition affects roughly one in eight women — more than 170 million worldwide. It is one of the most common endocrine conditions there is, and one of the most frequently missed.

The new name is being adopted over a three-year transition and will be fully implemented in the 2028 international guideline update. In practice both names are in circulation now: NHS laboratories have begun relabelling their reports, while most websites, most apps and most of the people who have the condition still say PCOS.

The consensus statement is blunt about it. The old name "reduced a complex, long-term hormonal or endocrine disorder to a misunderstanding about cysts" — and the misunderstanding is total, because **there is no increase in abnormal cysts on the ovary** in this condition.

What ultrasound shows is a larger number of normal, immature follicles. Follicles are not cysts. They are the small fluid-filled sacs every ovary contains, each holding an egg that may or may not mature in a given cycle. In this condition more of them stall at an early stage, which looks distinctive on a scan and is nothing like the pathological cyst the word implies.

That mattered clinically rather than cosmetically. A name pointing at the ovaries sent the diagnostic question to a gynaecologist and the patient’s attention to her fertility, when the condition also involves insulin, androgens, body weight, cardiovascular risk and mental health. People went undiagnosed for years because a scan did not look the way the name led everyone to expect, and people who were diagnosed were frequently told nothing about the metabolic half of it.

As the patient representative on the consensus put it, the new name "leads with hormones and recognises the metabolic dimension of the condition." That is the entire point of the change, and it is the part that matters for weight.

If you have been told that you are not trying hard enough, this section is the reason that was wrong.

Insulin resistance is common in this condition and it occurs independently of body weight — thin women with PMOS have it too. When cells respond poorly to insulin, the pancreas compensates by producing more of it, so circulating insulin runs high. High insulin does two things at once that work against you.

First, insulin is a storage hormone. While it is elevated, the body is biased towards storing fat and away from releasing it. The same calorie deficit that would produce weight loss in someone else produces less in someone whose insulin is chronically raised.

Second, high insulin stimulates the ovaries to produce more androgens, and raised androgens worsen insulin resistance. That is a loop, not a line — each side of it feeds the other, which is why the condition is persistent and why interventions that touch only one side tend to disappoint.

This is also why the advice that works for other people lands so badly here. "Eat less and move more" is not wrong, it is incomplete, and being given incomplete advice repeatedly while it fails is how a metabolic condition becomes a story someone tells themselves about their own willpower.

Your diagnosis. If you were diagnosed with PCOS, you have PMOS. It is the same condition under a more accurate name, and nothing about your records, your history or your care is invalidated.

The diagnostic criteria. The rename did not alter how the condition is identified.

The treatments. The combined pill and other hormonal options for cycle regulation, metformin, treatments for excess hair growth and acne, fertility treatment where it is wanted, and weight management where weight is part of the picture — all unchanged.

What has changed is emphasis. A name that leads with the endocrine and metabolic dimensions makes it more likely that the metabolic half gets assessed, which for most people means blood glucose, lipids and blood pressure rather than another scan.

This needs stating carefully, because it is the point at which most writing on the subject becomes marketing.

No GLP-1 medicine is licensed for PMOS. Not Mounjaro, not Wegovy, not the tablets. The trial evidence in this specific population exists but is small and mostly short, and a handful of trials in a few hundred people is not the basis on which anyone should be told a medicine treats their condition. Anyone presenting a GLP-1 as a PMOS treatment is telling you something about themselves.

What is accurate is narrower. These medicines are licensed for weight management in adults with a BMI of 30 or above, or 27 to under 30 **in the presence of at least one weight-related comorbidity**. The licences list what counts, and the list includes dysglycaemia — prediabetes or type 2 diabetes — along with hypertension, dyslipidaemia and obstructive sleep apnoea.

PMOS itself is not on that list. But dysglycaemia is, and impaired glucose tolerance is common in this condition. So the question that decides eligibility between a BMI of 27 and 30 is not whether you have PMOS; it is whether you have been tested for the dysglycaemia that often accompanies it. A great many people have never had that test, which means a great many people do not know which side of the line they are on.

That is a conversation to have with a prescriber, with your actual blood results in front of you. It is also a reason to ask for those results if nobody has ever ordered them.

Practically, expect both. Your old letters say PCOS. Your newer laboratory reports may say PMOS. Support groups, apps and most of the internet will take years to catch up, and some of it never will.

When searching for information, search both names — you will find different material under each, and for now the larger body of useful writing is still filed under the old one. When speaking to a clinician, either is understood. When reading something published after May 2026 that still explains the condition purely in terms of ovarian cysts, you have learned something about how current it is.